Paratonia in dementia: A Systematic Review

Manuscript Number: 

20-0691R1

Author(s): 
Ivan Bautmans, Hans Drenth, Hans Hobbelen, Galit Kleiner, Lucio Marinelli, Sytse Zuidema

Disclosures

Ivan Bautmans

  • Nothing to Disclose

Hans Drenth

  • Nothing to Disclose

Hans Hobbelen

  • Nothing to Disclose

Galit Kleiner

  • Consulting Fees:
    In the last year: I have provided opinion to Sunovion Pharmaceuticals regarding their marketing strategy of their new product Kynmobi that will soon be launched in Canada. I have been on an advisory board for Allergan Pharmaceuticals to create guidelines for use of Botox following stroke
    Lecture Fees:
    I have provided two lectures to my colleagues in Neurology sponsored by Abbvie Pharmaceuticals I have served as an "expert" in a teaching forum discussing phenomenology and treatment of dystonia. This was in the form of a dinner presentation and was sponsored by Ipsen Pharmaceuticals
    Patents/Royalties
    I own global patents for the indication of Botulinum Toxin in the treatment of paratonia
    Grants
    • Agency: 
      Sunovion Pharmaceuticals through Parkinson's Study group
      Dates: 
      September 2018-December 2019
    • Agency: 
      Merz Pharmaceuticals
      Dates: 
      2011-2013

Lucio Marinelli

  • Nothing to Disclose

Sytse Zuidema

  • Nothing to Disclose